Avita Medical (ASX:AVH) launched wound care treatment Cohealyx in the US, according to a Friday filing with the Australian bourse.
Cohealyx is a collagen-based dermal matrix branded by Avita Medical and co-developed with Regenity Biosciences, the filing stated. It is designed to provide wound bed through cellular migration and revascularization for faster closure.
Avita Medical is enrolling participants in the Cohealyx I post-market trial.
The company's shares were down almost 4% in recent Friday trade.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。